340022-81-3

Upstream product

• 57899-62-4 triethyl 4-oxocyclohexane-1,1,3-tricarboxylate 
• 17159-79-4 ethyl 4-oxocyclohexane-1-carboxylate 
• 107704-10-9 4,4-dimethoxycyclohexancarbonsaureethylester 
• 1257050-69-3 1,4-dioxaspiro[4.5]decane-8,8-diylbis(methylene) bis(4-methylbenzenesulfonate) 
• 92454-00-7 pentane-1,3,3,5-tetracarboxylic acid-3,3-diethyl ester 
• 1256546-72-1 [8-(hydroxymethyl)-1,4-dioxaspiro[4.5]decan-8-yl]methanol 
• 1256546-71-0 8,8-diethyl 1,4-dioxaspiro[4.5]decane-8,8-dicarboxylate 
• 55704-60-4 4-oxo-cyclohexane-1,1-dicarboxylic acid diethyl ester 

Downstream Products

• 1380664-91-4 (4-amino-4-cyanocyclohexane-1,1-diyl)bis(methylene)bis(4-methylbenzenesulfonate) 
• 1380665-32-6 N-[7-(chloromethyl)-2-[[[(4-fluoro-3-methylphenyl)methyl]amino]carbonyl]-6,7,8,9-tetrahydro-3-hydroxy-4-oxo-7,10-ethanopyrimido[1,2-a]azepin-10(4H)-yl]-carbamic acid phenylmethyl ester 
• 1380665-41-7 N'-[2-[[[(4-fluoro-3-methylphenyl)methyl]amino]carbonyl]-6,7,8,9-tetrahydro-7-(hydroxymethyl)-4-oxo-3-(phenylmethoxy)-7,10-ethanopyrimido[1,2-a]azepin-10(4H)-yl]-N,N-dimethyl-ethanediamide 
• 1380662-06-5 N'-[2-[[[(4-fluoro-3-methylphenyl)methyl]amino]carbonyl]-6,7,8,9-tetrahydro-3-hydroxy-7-(hydroxymethyl)-4-oxo-7,10-ethanopyrimido[1,2-a]azepin-10(4H)-yl]-N,N-dimethyl-ethanediamide 
• 1380665-45-1 N₂-[2-[[[(4-fluoro-3-methylphenyl)methyl]amino]carbonyl]-7-formyl-6,7,8,9-tetrahydro-4-oxo-3-(phenylmethoxy)-7,10-ethanopyrimido[1,2-a]azepin-10(4H)-yl]-N₁,N₁-dimethyl-ethanediamide 
• 1380665-42-8 N₂-[2-[[[(4-fluoro-3-methylphenyl)methyl]amino]carbonyl]-6,7,8,9-tetrahydro-4-oxo-3-(phenylmethoxy)-7-[[(tetrahydro-2H-pyran-4-yl)amino]methyl]-7,10-ethanopyrimido[1,2-a]azepin-10(4H)-yl]-N₁,N₁-dimethyl-ethanediamide 
• 1380662-05-4 N'-[2-[[[(4-fluoro-3-methylphenyl)methyl]amino]carbonyl]-6,7,8,9-tetrahydro-3-hydroxy-7-[[[(4-methylphenyl)sulfonyl]oxy]methyl]-4-oxo-7,10-ethanopyrimido[1,2-a]azepin-10(4H)-yl]-N,N-dimethyl-ethanediamide 
• 1380662-19-0 N-[2-[[[(4-fluoro-3-methylphenyl)methyl]amino]carbonyl]-6,7,8,9-tetrahydro-3-hydroxy-7-(hydroxymethyl)-4-oxo-7,10-ethanopyrimido[1,2-a]azepin-10(4H)-yl]-n,N',N'-trimethyl-ethanediamide 
• 1380662-28-1 N-[7-(cyanomethyl)-2-[[[(4-fluoro-3-methylphenyl)methyl]amino]carbonyl]-6,7,8,9-tetrahydro-3-hydroxy-4-oxo-7,10-ethanopyrimido[1,2-a]azepin-10(4H)-yl]-n,N',N'-trimethyl-ethanediamide 
• 1380662-29-2 N-[7-(fluoromethyl)-2-[[[(4-fluoro-3-methylphenyl)methyl]amino]carbonyl]-6,7,8,9-tetrahydro-3-hydroxy-4-oxo-7,10-ethanopyrimido[1,2-a]azepin-10(4H)-yl]-N,N',N'-trimethyl-ethanediamide 
• 1380662-30-5 N-[2-[[[(4-fluoro-3-methylphenyl)methyl]amino]carbonyl]-6,7,8,9-tetrahydro-3-hydroxy-7-(methoxymethyl)-4-oxo-7,10-ethanopyrimido[1,2-a]azepin-10(4H)-yl]-N,N',N'-trimethyl-ethanediamide 
• 1380662-31-6 N-[7-(cyanomethyl)-2-[[[(4-fluorophenyl)methyl]amino]carbonyl]-6,7,8,9-tetrahydro-3-hydroxy-4-oxo-7,10-ethanopyrimido[1,2-a]azepin-10(4H)-yl]-n,N',N'-trimethyl-ethanediamide 
• 1380662-35-0 N-[7-(fluoromethyl)-2-[[[(4-fluorophenyl)methyl]amino]carbonyl]-6,7,8,9-tetrahydro-3-hydroxy-4-oxo-7,10-ethanopyrimido[1,2-a]azepin-10(4H)-yl]-n,N',N'-trimethyl-ethanediamide 
• 1380662-90-7 N'-[7-(chloromethyl)-2-[[[(4-fluoro-3-methylphenyl)methyl]amino]carbonyl]-6,7,8,9-tetrahydro-3-hydroxy-4-oxo-7,10-ethanopyrimido[1,2-a]azepin-10(4H)-yl]-N,N-dimethyl-ethanediamide 

Relevant academic research and scientific papers

Identification of potent, selective and orally bioavailable phenyl ((R)-3-phenylpyrrolidin-3-yl)sulfone analogues as RORγt inverse agonists

An X-ray crystal structure of one of our previously discovered RORγt inverse agonists bound to the RORγt ligand binding domain revealed that the cyclohexane carboxylic acid group of compound 2 plays a significant role in RORγt binding, forming four hydrog

OXABICYCLO [2.2.2] ACID GPR120 MODULATORS

The present invention provides compounds of Formula (I): or a stereoisomer, or a pharmaceutically acceptable salt thereof, wherein all of the variables are as defined herein. These compounds are GPR120 G protein-coupled receptor modulators which may be used as medicaments.

Oxabicyclooctane-linked novel bacterial topoisomerase inhibitors as broad spectrum antibacterial agents

Bacterial resistance is eroding the clinical utility of existing antibiotics necessitating the discovery of new agents. Bacterial type II topoisomerase is a clinically validated, highly effective, and proven drug target. This target is amenable to inhibit

BRIDGED BICYCLIC COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS

Novel bridged bicyclic compounds are disclosed herein, along with their pharmaceutically acceptable salts, hydrates and prodrugs. Also disclosed are compositions comprising such compounds, methods of preparing such compounds and methods of using such compounds as antibacterial agents. The disclosed compounds, their pharmaceutically acceptable salts, hydrates and prodrugs, as well as compositions comprising such compounds, salts, hydrates and prodrugs, are useful for treating bacterial infections and associated diseases and conditions.

HIV INTEGRASE INHIBITORS

The disclosure generally relates to the novel compounds of formula (I), including their salts, which inhibit HIV integrase and prevent viral integration into human DNA. This action makes the compounds useful for treating HIV infection and AIDS. The invent